메뉴 건너뛰기
Neurology
Volumn 82, Issue 24, 2014, Pages 2150-2151
Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab
Author keywords

[No Author keywords available]
Indexed keywords

ALEMTUZUMAB; CD4 ANTIGEN;
EID: 84903954136     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000530     Document Type: Editorial
Times cited : (8)
References (8)
  • 1
    • 80053207130 scopus 로고    scopus 로고
    • Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
    • Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77: 573-579.
    • (2011) Neurology , vol.77 , pp. 573-579
    • Cossburn, M.1    Pace, A.A.2    Jones, J.3
  • 2
    • 0033552391 scopus 로고    scopus 로고
    • Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
    • Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354: 1691-1695.
    • (1999) Lancet , vol.354 , pp. 1691-1695
    • Coles, A.J.1    Wing, M.2    Smith, S.3
  • 3
    • 84860780657 scopus 로고    scopus 로고
    • Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of camms223 clinical trial
    • Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78: 1069-1078.
    • (2012) Neurology , vol.78 , pp. 1069-1078
    • Coles, A.J.1    Fox, E.2    Vladic, A.3
  • 4
    • 0032882173 scopus 로고    scopus 로고
    • Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
    • Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46: 296-304.
    • (1999) Ann Neurol , vol.46 , pp. 296-304
    • Coles, A.J.1    Wing, M.G.2    Molyneux, P.3
  • 5
    • 40149098173 scopus 로고    scopus 로고
    • Campath 1-h treatment in patients with aggressive relapsing remitting multiple sclerosis
    • Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255: 231-238.
    • (2008) J Neurol , vol.255 , pp. 231-238
    • Hirst, C.L.1    Pace, A.2    Pickersgill, T.P.3
  • 6
    • 27944439639 scopus 로고    scopus 로고
    • Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
    • Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35: 3332-3342.
    • (2005) Eur J Immunol , vol.35 , pp. 3332-3342
    • Cox, A.L.1    Thompson, S.A.2    Jones, J.L.3
  • 7
    • 84873690365 scopus 로고    scopus 로고
    • Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
    • Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013;80: 55-61.
    • (2013) Neurology , vol.80 , pp. 55-61
    • Cossburn, M.D.1    Harding, K.2    Ingram, G.3
  • 8
    • 84903985522 scopus 로고    scopus 로고
    • Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
    • Kousin-Ezewu O, Azzopardi L, Parker RA, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 2014;82: 2158-2164.
    • (2014) Neurology , vol.82 , pp. 2158-2164
    • Kousin-Ezewu, O.1    Azzopardi, L.2    Parker, R.A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.